GERN

Geron Corp

• Seeking Alpha·07/01 14:11

  Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up

• Reuters·06/18 20:01

  GERON CORPORATION REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• PUBT·06/12 18:57

  Geron posts presentation on real-world imetelstat outcomes in heavily pretreated lower-risk MDS patients

• NASDAQ·06/04 13:35

  After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)

• PUBT·06/01 22:00

  Geron publishes IMbark imetelstat myelofibrosis survival presentation

• PUBT·06/01 12:04

  Geron management to speak at Goldman Sachs Global Healthcare Conference fireside chat

• Seeking Alpha·06/01 09:53

  Geron: Time To Reconsider This Oversold Biotech

• TipRanks·05/27 21:04

  Geron Shareholders Expand Equity Plan and Elect Directors

• PUBT·05/27 20:04

  Geron holds annual shareholder meeting, backs 4,500,000-share increase to equity plan

• TipRanks·05/20 01:57

  Geron Earnings Call Highlights Growth, Pricing Pressures

• PUBT·05/18 20:01

  Geron grants 333,750 inducement stock options to new hires at $1.29 per share

• Reuters·05/18 20:01

  GERON CORPORATION REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• TipRanks·05/12 19:13

  Geron to present RWE study of RYTELO at EHA Congress

• Benzinga·05/12 13:35

  Geron To Present Real-World Moffitt Cancer Center Study Showing RYTELO (imetelstat) Safety And Efficacy In Lower-Risk MDS At EHA 2026

• PUBT·05/12 13:33

  Geron reports real-world RYTELO study shows 37.5% transfusion independence in lower-risk MDS